ingn 201
Trade name: advexin
Gene therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 11, 2002 (NCT00041626)
Timeline
Indications
Mechanism of action
- Cellular tumor antigen p53Supplementation
TP53 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- advexin
- ingn 201
- ingn 201
- ingn 201
- ingn-201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00286247 | Phase 2 | Feb 1, 2006 | Introgen Therapeutics |
| NCT00410865 | Phase 1 | Jun 1, 2003 | Department of Health and Human Services, National Cancer Institute (NCI), University of Texas at Houston |
| NCT00041613 | Phase 3 | Jul 11, 2002 | Introgen Therapeutics |
| NCT00041626 | Phase 3 | Jul 11, 2002 | Introgen Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Introgen Therapeutics | For profit | 3 | 3 | 2 | 2002 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2003 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2003 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2003 |
4 organizations
Page 1 / 1